| Literature DB >> 25187273 |
Chad Tang1, Xiaohong Wang1, Hendrick Soh2, Steven Seyedin1, Maria Angelica Cortez1, Sunil Krishnan1, Erminia Massarelli3, David Hong4, Aung Naing4, Adi Diab5, Daniel Gomez1, Huiping Ye1, John Heymach3, Ristuko Komaki1, James P Allison6, Padmanee Sharma7, James W Welsh8.
Abstract
With the recent success of checkpoint inhibitors and other immunomodulating agents, there has been renewed interest in the combination of such agents with radiation. The biologic premise behind such a strategy is that the tumor-antigen release achieved by localized radiation will promote specific tumor targeting by the adaptive immune system, which can be augmented further by systemic immune-stimulating agents. In this manner, clinicians hope to induce a phenomenon known as the abscopal effect, whereby localized radiation results in immune-mediated tumor regression in disease sites well outside of the radiation field. Herein, we present a comprehensive overview of the early clinical and preclinical evidence behind this approach. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25187273 PMCID: PMC5367158 DOI: 10.1158/2326-6066.CIR-14-0069
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151